Full Press Release Details
Tonix Pharmaceuticals Holding Corp. 8-K
Tonix Pharmaceuticals Initiates Enrollment in the
RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Results from Planned Interim Analysis Expected First
A Positive Outcome in RESILIENT Together with Results
from Previous Positive Phase 3 Study RELIEF May Support Submission of an NDA
CHATHAM, N.J., April 7, 2022 (GLOBE NEWSWIRE)
- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced
that the first participant was enrolled in the Phase 3 RESILIENT study of TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets)
5.6 mg for the management of fibromyalgia.
RESILIENT is the Company's potentially
pivotal Phase 3 study of TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine HCl taken daily at bedtime for the
management of fibromyalgia. An interim analysis by an Independent Data Monitoring Committee of the first 50% of enrolled patients for
a potential sample size readjustment or early stop for futility is expected in the first quarter of 2023.
TNX-102 SL is in mid-Phase 3 development for the management
of fibromyalgia. In December 2020, Tonix reported positive results from the first Phase 3 study (RELIEF) of TNX-102 SL 5.6 mg for the
management of fibromyalgia (primary endpoint, p=0.010). Several secondary measures in RELIEF highlighted the broad effects of TNX-102
SL across several cardinal symptoms of fibromyalgia beyond pain. In March 2022, Tonix reported results of a subsequent Phase 3 study (RALLY)
in which TNX-102 SL did not achieve statistical significance on the primary endpoint (p=0.115). Relative to the previous positive
Phase 3 study (RELIEF), RALLY had an unexpected increase in study participant adverse event-related discontinuations in both the drug
"Tonix remains dedicated to improving the lives
of the millions suffering from fibromyalgia and we are pleased to have our confirmatory, potentially pivotal Phase 3 RESILIENT study getting
underway," said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "Fibromyalgia is a complex syndrome
in which many patients remain unsatisfied by existing treatment options. Based on the positive results from RELIEF study, together with
our general understanding of TNX-102 SL tolerability, we are excited to initiate our new RESILIENT Phase 3 study for fibromyalgia."
"Fibromyalgia is a pain disorder characterized
by chronic widespread pain, non-restorative sleep, fatigue, and impaired cognition," said Gregory Sullivan, M.D., Chief Medical
Officer of Tonix Pharmaceuticals. "Approximately one-fourth of people with fibromyalgia resort to prescription opioids for analgesia2.
TNX-102 SL is a centrally acting analgesic that has the potential to be a new non-addictive, non-opioid bedtime medication for the management
of fibromyalgia with broad spectrum symptom coverage. Symptoms of fibromyalgia overlap with those
of other chronic pain conditions, which as a group have been termed, chronic overlapping pain conditions.'3,4
This type of pain syndrome is increasingly recognized as nociplastic pain',5 and the underlying mechanism
is termed central sensitization.'6 Opiates are generally not recommended
for fibromyalgia or other nociplastic pain syndromes."
SL is an investigational new drug and has not been approved for any indication.
2Sarmento, CVM, et al. (2019)
"Opioid prescription patterns among patients with fibromyalgia." J Opioid Manag. 15(6):469-477. doi: 10.5055/jom.2019.0537.
W, et al.. (2016) "Overlapping Chronic Pain Conditions: Implications for Diagnosis and Classification". J Pain. 17(9
C, et al. (2015): Impact of chronic overlapping pain conditions on public health and the urgent need for safe and effective treatment:
2015 analysis and policy recommendations. Chronic Pain Research Alliance. http://www.chronicpainresearch. org/public/CPRA_WhitePaper_2015-FINAL-Digital.pdf.
Accessed July 26, 2021.
AP, Perrot S. (2019) "New concepts of pain". Best Pract Res Clin Rheumatol. 33(3):101415.
J, George SZ, Clauw DJ, et al. (2021) "Central sensitisation in chronic pain conditions: latest discoveries and their potential
for precision medicine". The Lancet Rheumatology. 3(5):e383-e392. doi:10.1016/s2665-9913(21)00032-1
About the Phase 3 RESILIENT Study
The RESILIENT study is a double-blind, randomized,
placebo-controlled trial designed to evaluate the efficacy and safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the management
of fibromyalgia. The two-arm trial is expected to enroll approximately 470 participants in the U.S. The first two weeks of treatment consist
of a run-in period in which participants start on TNX-102 SL 2.8 mg (1 tablet) or placebo. Thereafter, all participants increase their
dose to TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) or two placebo tablets for the remaining 12 weeks. The primary endpoint is the daily diary
pain severity score change (TNX-102 SL 5.6 mg vs. placebo) from baseline to Week 14 (using the weekly averages of the daily numerical
rating scale scores), analyzed by mixed model repeated measures with multiple imputation. An interim analysis by an Independent Data Monitoring
Committee will be conducted on the primary endpoint based on the first 50% of enrolled participants for a potential sample size readjustment
or early stop for futility.
For more information, see ClinicalTrials.gov Identifier:
Fibromyalgia is a chronic pain disorder that is understood
to result from amplified sensory and pain signaling within the central nervous system. Fibromyalgia afflicts an estimated 6-12 million
adults in the U.S., approximately 90% of whom are women. Symptoms of fibromyalgia include chronic widespread pain, nonrestorative sleep,
fatigue, and morning stiffness. Other associated symptoms include cognitive dysfunction and mood disturbances, including anxiety and depression.
Individuals suffering from fibromyalgia struggle with their daily activities, have impaired quality of life, and frequently are disabled.
Physicians and patients report common dissatisfaction with currently marketed products.
TNX-102 SL is a patented sublingual tablet
formulation of cyclobenzaprine hydrochloride which provides rapid transmucosal absorption and reduced production of a long half-life active
metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. As a multifunctional agent with potent binding and antagonist
activities at the 5-HT2A-serotonergic, 1-adrenergic, H1-histamine, and M1-muscarinic
receptors, TNX-102 SL is in development as a daily bedtime treatment for fibromyalgia, PTSD, Long COVID (formally known as post-acute
sequelae of COVID-19 [PASC]), alcohol use disorder and agitation in Alzheimer's disease. The United States Patent and Trademark
Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018,
Patent No. 10,357,465 in July 2019, and Patent No. 10736859 in August 2020. The Protectic protective eutectic and Angstro-Technology
formulation claimed in the patent are important elements of Tonix's proprietary TNX-102 SL composition. These patents are expected
to provide TNX-102 SL, upon NDA approval, with U.S. market exclusivity until 2034/2035.
About Tonix Pharmaceuticals Holding Corp.
Tonix is a clinical-stage biopharmaceutical
company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and
alleviate suffering. Tonix's portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS)
product candidates. Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer,
including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft
and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second
half of 2022. Tonix's rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900
has been granted Orphan-Drug Designation by the FDA. Tonix's infectious disease pipeline includes a vaccine in development to prevent
smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix's
lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix's recombinant
pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat
acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug
being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID
in the second quarter of 2022. The Company's CNS portfolio includes both small molecules and biologics to treat pain, neurologic,
psychiatric and addiction conditions. Tonix's lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of
fibromyalgia with a new Phase 3 study now launched in the second quarter of 2022. Finally, TNX-13006 is a biologic designed
to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022.
is an investigational new biologic at the pre-IND stage of development and has not been approved for any indication.
is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
is a live horsepox virus vaccine for percutaneous administration in development to protect against smallpox and monkeypox. TNX-801 is
an investigational new biologic and has not been approved for any indication.
and TNX-1850 are live horsepox virus vaccines for percutaneous administration, in development to protect against COVID-19. TNX-1840 and
TNX-1850 are designed to express the SARS-CoV-2 spike protein from the omicron and BA.2 variants, respectively. TNX-1840 and TNX-1850
are investigational new biologics at the pre-IND stage of development and have not been approved for any indication.
is an investigational new drug at the pre-IND stage of development and has not been approved for any indication.
is an investigational new biologic and has not been approved for any indication.
This press release and further information about Tonix
can be found at www.tonixpharma.com.